13F Data
13F filer · CIK 1121404

Sanofi

Paris, I0 · filing since Q4 2024 · last filing Nov 5, 2026
Reported value
$629.9M
+$95.8M vs prior
Positions
16
New / sold out
6 / 0
Added / reduced
0 / 1
Turnover
0.0%
buys $137.5M · sells $38.2K
Top-10 weight
92.1%

Biggest buys vs Q2 2026

ChangeSecurityShares changeChange %Est. trade value
NewKorsana Biosciences+1,994,011–+$63.8M
NewElectra Therapeutics Inc+2,461,948–+$27.7M
NewAttovia Therapeutics Inc+1,082,855–+$18.6M
NewLatigo Biotherapeutics Inc+672,778–+$11.2M
NewScribe Therapeutics+500,000–+$9.2M
NewSAB BIOTHERAPEUTICS INC+2,198,500–+$7.0M

Biggest sells vs Q2 2026

ChangeSecurityShares changeChange %Est. trade value
ReducedOdyssey Therapeutics Inc.-1,718-0.1%$-38.2K

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2024: $174.4MQ1 2025: $165.9MQ2 2025: $175.7MQ3 2025: $260.4MQ4 2025: $310.4MQ1 2026: $336.0MQ2 2026: $534.0MQ3 2026: $629.9M
Q4 2024Q3 2026

Holdings · Q3 2026

#SecuritySharesValueWeight
1MeiraGTx Holdings plcCOM12,197,737$134.2M21.30%
2Inhibrx Biosciences, Inc.COM1,157,926$115.9M18.40%
3NovavaxCOM NEW6,880,481$74.4M11.81%
4Korsana BiosciencesCOM1,994,011$63.8M10.13%
5Odyssey Therapeutics Inc.COMMON STOCK1,990,200$44.2M7.02%
6AnaptysBioCOM821,917$41.3M6.56%
7Agomab Therapeutics NVSPONSORED ADS2,783,096$30.9M4.90%
8First Tracks Biotherapeutics Inc.ORD SHS821,917$29.1M4.62%
9Electra Therapeutics IncCOM2,461,948$27.7M4.40%
10Attovia Therapeutics IncCOM1,082,855$18.6M2.95%
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.